Company Filing History:
Years Active: 2011
Title: Kimishisa Ichikawa: Innovator in Antibody Research
Introduction
Kimishisa Ichikawa is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of antibody research, particularly in the development of antibodies that target specific receptors involved in apoptosis and cell growth regulation. His work has implications for treating various diseases related to cell proliferation and apoptosis.
Latest Patents
Ichikawa holds a patent for an "Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof." This innovative antibody interacts with the human DR5 receptor, producing either agonistic or antagonistic effects downstream. The patent details the nucleic acid and amino acid sequences of anti-DR5 antibodies, along with methods for their use in treating apoptosis-related diseases and dysregulated cell growth. He has 1 patent to his name.
Career Highlights
Ichikawa is associated with the UAB Research Foundation, where he continues to advance his research in antibody development. His work has garnered attention for its potential applications in medical treatments, particularly in oncology and other fields where cell regulation is crucial.
Collaborations
Ichikawa has collaborated with notable colleagues, including Tong Zhou and Robert P Kimberly. These partnerships have enhanced the scope and impact of his research, contributing to advancements in the understanding of apoptosis and cell growth mechanisms.
Conclusion
Kimishisa Ichikawa's innovative work in antibody research exemplifies the potential of targeted therapies in medicine. His contributions are paving the way for new treatments that address critical health challenges.